Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERIKA neoadjuvant endocrine therapy trial in hormone receptor-positive HER2-negative early breast cancer
2023-505758-17-00Phase 2Authorised
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of elacestrant, ribociclib, letrozole, anastrozole and exemestane in breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Proportion of modified PEPI score of 0 at surgery. Planned start Aug 2025; status: authorised.
02
Drugs
elacestrantribociclibletrozoleanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505758-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505758-17-00.